article
Pharma patent challenges for 2018
Christof Hohne, partner at patent law firm EIP, discusses second medical use claims and compulsory licences...
List view / Grid view
Actavis
news
Shire wins Lialda patent trial against Watson
29 March 2016 | By Victoria White
The US District Court for Southern Florida has upheld Shire's patent for Lialda (mesalamine) delayed release tablets for adults with ulcerative colitis...
article
European Pharmaceutical Review’s top 10 stories from 2015
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
news
UK court rules in favour of Lilly in Alimta vitamin regimen patent lawsuit
26 June 2015 | By Victoria White
The UK Court of Appeal has ruled in favour of Lilly in the Actavis v. Eli Lilly and Company Alimta vitamin regimen patent lawsuit...
news
Actavis responds to SMC’s reccommendation of Ozurdex as a valuable treatment option for patients with diabetic macular oedema
13 May 2015 | By
Actavis has responded to the decision by the SMC to accept Ozurdex for use by NHS Scotland for the treatment of visual impairment in patients with DMO...
news
Actavis receives FDA approval of SAPHRIS® for pediatric patients (age 10-17) for acute treatment of manic or mixed episodes of bipolar I disorder
13 March 2015 | By Actavis
Actavis plc announced that the U.S. Food and Drug Administration has approved its supplemental new drug application (sNDA) for SAPHRIS® (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients...
news
Actavis to acquire Auden Mckenzie for £306m
27 January 2015 | By Actavis
Actavis plc and the owners of Auden Mckenzie Holdings Limited, a dynamic and fast growing company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the UK, announced that they have reached a definitive agreement, under which Actavis will acquire Auden Mckenzie for approximately…
news
Munich named as top location for biotechnology and pharmaceutical industries
24 November 2014 | By BioM Biotech Cluster Development GmbH
Munich is the top location for biotechnology and pharmaceutical industries according to a new study by the Chamber of Industry and Commerce (IHK)...
news
Actavis continues consolidation March with highly priced allergan deal, says GlobalData director
18 November 2014 | By Actavis
Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “Actavis has agreed to purchase Allergan for around $66 billion, in a deal which draws to an end Valeant’s lengthy wrangle to acquire the Botox manufacturer..."
news
FDA Advisory Committee recommends against approval of Actavis’ Nebivolol/Valsartan fixed-dose combination NDA for treatment of hypertension
10 September 2014 | By Actavis
Actavis plc confirmed that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension...
news
Actavis confirms generic Diclegis® Patent challenge
15 July 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets...
news
Actavis confirms Generic Ampyra® patent challenge
9 July 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Dalfampridine Extended-release Tablets, 10 mg...
news
Actavis plc appoints new members and announces changes to Board of Directors following close of Forest Laboratories, Inc. acquisition
2 July 2014 | By Actavis
Actavis plc announced the appointment of three new members to the Company's Board of Directors, including Actavis' newly appointed CEO and President, Brenton L. Saunders...
news
Michael Cann picks up the reins at the BGMA
26 May 2010 | By College Hill
Michael Cann, Director Generics at Actavis, took over as Chairman of the BGMA at the Association’s AGM in London on 26 May. He replaces Kim Innes of Teva, who will serve as Vice Chair for a year.
